Selank Dosage Chart for a 10 mg Vial
This Selank dosage chart explains 10 mg vial reconstitution, concentration, and intranasal research calculations for a verified 0.10 mL metered actuator. Published human Selank research primarily used intranasal drops or measured intranasal solution. A measured 5 mL final volume provides 200 mcg each actuation, while a measured 10 mL final volume provides 100 mcg each actuation.
- Primary human research route: Intranasal drops or measured intranasal solution.
- 5 mL final volume: 2 mg/mL, 200 mcg at each verified 0.10 mL actuation, and 50 nominal actuations.
- 10 mL final volume: 1 mg/mL, 100 mcg at each verified 0.10 mL actuation, and 100 nominal actuations.
- Device check: Confirm the pump output and follow its priming instructions before using the calculation.
- Research context: Human studies used different amounts, durations, and manufactured drop formulations.
Selank is a synthetic heptapeptide based on the naturally occurring tuftsin sequence. Human research has evaluated intranasal Selank in adults with generalized anxiety disorder, neurasthenia, and in acute neuroimaging experiments[1][2][4]. The calculations below use the entire 10 mg vial and keep published study protocols separate from worked preparation examples.
Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read Selank Peptide: Benefits, Uses, Side Effects, Dosage, and Research.
Selank Dosage and Reconstitution Chart
Selank 10 mg intranasal research calculations for 5 mL and 10 mL final volumes
Selank 10 mg Nasal Spray Dosage Calculations
Each option begins with 3.0 mL in the peptide vial. Transfer the complete solution, then add enough vehicle to reach the measured final volume.
| Measured Final Volume | Vehicle Added After Transfer | Final Concentration | Per Verified 0.10 mL actuation |
|---|---|---|---|
| 5.0 mL | About 2.0 mL | 2,000 mcg/mL | 200 mcg 50 nominal actuations |
| 10.0 mL | About 7.0 mL | 1,000 mcg/mL | 100 mcg 100 nominal actuations |
| 6.67 mL (registered-product concentration reference) | About 3.67 mL | 1,500 mcg/mL | 150 mcg 66.7 nominal actuations |
Published Intranasal Research Schedule
| Period | Amount | actuation Volume | Frequency |
|---|---|---|---|
| Days 1–14 | 300 mcg per administration (900 mcg/day) | 0.20 mL at 1.5 mg/mL (2 verified 0.10 mL actuations) | 3 times daily |
Research reference only: This translates the registered 0.15% Selank drop schedule into volume for a verified 0.10 mL actuator. A custom research solution and pump are not equivalent to the registered preserved formulation.
Calculation basis: Each row uses the full 10 mg vial and a pump verified to release 0.10 mL per complete actuation. Nominal actuation counts are calculated before priming and normal residual hold-up.
How to Prepare the 5 mL or 10 mL Research Bottle
- Confirm: Verify the 10 mg vial, compatible sterile research vehicle, actuator bottle capacity, and documented pump output.
- Dissolve: Add 3.0 mL of compatible sterile vehicle to the vial with aseptic transfer technique, then gently swirl until dissolved. Do not shake.
- Transfer and measure: Transfer the complete solution into the sterile actuator bottle and add enough vehicle to reach exactly 5.0 mL or 10.0 mL final volume.
- Label and prime: Secure the pump; label the peptide amount, final volume, concentration, pump output, and preparation date; then prime according to the actuator instructions and record the priming actuations.
Vehicle context: The worked example can use sterile 0.9% saline as a research vehicle. The registered 0.15% Selank product contains 1.5 mg/mL Selank in purified water with methylparaben, so the saline example is not the same as the manufactured multidose drop formulation.
Mathematical Actuator Equivalents
| Literature Amount | 5 mL Option 200 mcg each actuation |
10 mL Option 100 mcg each actuation |
|---|---|---|
| 300 mcg | 1.5 theoretical actuations | 3 actuations |
| 900 mcg | 4.5 theoretical actuations | 9 actuations |
| 2,700 mcg | 13.5 theoretical actuations | 27 actuations |
These rows are concentration conversions, not a universal schedule. Fractional results are mathematical only because a metered pump cannot deliver half of a full actuation. Amounts reported with a manufactured drop formulation should not be treated as direct generic-pump instructions.
Published Intranasal Selank Clinical Studies
Human Selank anxiolytic research has primarily used the intranasal route. The studies below show the reported amount, formulation, and research setting so visitors can compare the literature without treating different protocols as interchangeable.
| Source | Research Context | Published Intranasal Amount and Formulation |
|---|---|---|
| Zozulia et al., 2008[1] | 62 adults with GAD or neurasthenia | Selank 0.15% nasal drops at 2.7 mg per day, reported as 36 drops divided across three administrations, with outcomes followed through day 14. |
| Syunyakov et al., 2012[2] | 20 adults with GAD | 2,700 mcg per day intranasally. The pharmaco-EEG analysis also examined a single 900 mcg exposure. |
| Panikratova et al., 2020[4] | Healthy-volunteer functional connectivity study | One intranasal exposure using 0.15% Selank solution, 60 microliters per nostril, described as a 0.2 mg total amount. |
The current manufacturer instruction describes a 0.15% nasal-drop product at 1.5 mg/mL, with two drops placed in each nasal passage three times daily for 14 days. Those drop counts belong to the registered bottle and finished formulation. They are not direct equivalents to a different metered pump.
Reference concentration: Mathematically, 10 mg brought to about 6.67 mL equals 1.5 mg/mL. A verified 0.10 mL actuation at that concentration contains 150 mcg. This is a concentration comparison, not a reproduction of the registered preserved drop product.
Selank Nasal Spray Actuator Math
A 0.10 mL actuator is a common nasal pump configuration, but pump output is not universal. Pharmaceutical literature reports pump volumes from approximately 0.025 mL to 0.20 mL per actuation[5]. Use the manufacturer specification or a validated measurement for the exact device.
Core Formula
mcg per actuation = (10,000 mcg / final volume in mL) x verified mL per actuation
nominal actuations = final volume in mL / verified mL per actuation
| Verified Actuator Output | 5 mL Option 2,000 mcg/mL |
10 mL Option 1,000 mcg/mL |
|---|---|---|
| 0.05 mL | 100 mcg | 50 mcg |
| 0.10 mL | 200 mcg | 100 mcg |
| 0.13 mL | 260 mcg | 130 mcg |
Actuator Checks Before Recording a Result
- Confirm the stated volume per full actuation for the specific pump.
- Follow the documented priming and repriming procedure.
- Record residual volume and tail-off near bottle exhaustion when estimating usable actuations.
- Keep pump orientation and actuation stroke consistent during the research procedure.
FDA nasal spray guidance treats pump delivery, priming, dose uniformity, and bottle exhaustion as product performance variables[6].
Supplies Needed
Use one complete set of measured and sterile research supplies for each prepared Selank 10 mg nasal bottle.
- Selank 10 mg research vial: One vial per prepared bottle, with lot-specific identity, purity, and assay documentation. The supplier card below links to the existing Selank 10 mg product page.[8]
- Sterile research vehicle: Single-use sterile 0.9% sodium chloride for the worked saline example, or another validated sterile nasal research vehicle.
- Sterile nasal actuator bottle: One 5 mL or 10 mL bottle intended for single-user research.
- Metered pump: A compatible actuator documented or verified at 0.10 mL per complete actuation.
- Calibrated transfer tools: Sterile syringes or pipettes that can measure the initial 3.0 mL and the exact 5.0 mL or 10.0 mL final volume.
- Sterile transfer needle: Required when the peptide vial uses a rubber septum.
- Clean handling supplies: Alcohol preparation pads, clean gloves, and a disinfected work surface.
- Label and research log: Record the peptide amount, final volume, concentration, pump output, preparation date, priming actuations, and actuation count.
- Storage materials: Light-protective, temperature-controlled storage appropriate to the validated formulation.
- Sharps container: Use when transfer needles are part of the preparation workflow.
Research Protocol Overview
Quick reference for the intranasal Selank 10 mg calculation.
- Human research route: Intranasal drops or solution.
- Peptide amount: 10,000 mcg total in the vial.
- 5 mL option: 2,000 mcg/mL and 200 mcg at each verified 0.10 mL actuation.
- 10 mL option: 1,000 mcg/mL and 100 mcg at each verified 0.10 mL actuation.
- Final-volume rule: Bring the transferred solution to an exact measured final volume.
Research Amount Calculator
Mathematical equivalents for a verified 0.10 mL actuator.
- 300 mcg: 1.5 theoretical actuations at 5 mL or 3 actuations at 10 mL.
- 900 mcg: 4.5 theoretical actuations at 5 mL or 9 actuations at 10 mL.
- 2,700 mcg: 13.5 theoretical actuations at 5 mL or 27 actuations at 10 mL.
- Whole vial: 50 nominal actuations at 5 mL or 100 nominal actuations at 10 mL.
- Interpretation: Fractional values are mathematical only. Match each amount to its original study, dropper, and formulation context.
Storage Instructions
Storage depends on the complete formulation, container, and handling method.
- Registered 0.15% product: Protected from light, stored at no more than 10 degrees C, and not frozen.
- Opened registered product: Follow that finished product’s manufacturer instructions; its labeled conditions do not apply to a custom research preparation.
- Custom research preparation: Use formulation-specific stability and microbiological controls rather than transferring the finished-product shelf life.
- Labeling: Record preparation date, final volume, concentration, vehicle, and storage conditions.
Important Notes
Small measurement and device details can materially change the amount delivered per actuation.
- Use a measured final volume, not the bottle capacity mark alone.
- Verify that the actuator releases 0.10 mL per full stroke before applying the main table.
- Prime and reprime exactly as specified for the pump, then record those actuations.
- Keep the bottle upright and use a complete, consistent stroke for each recorded actuation.
- Treat the theoretical 50 or 100 actuations as nominal counts because priming and residual hold-up consume part of the volume.
- A 10 mg vial contains 10,000 mcg total. Calculate the complete peptide requirement before modeling any multi-day published protocol.
- Use a validated laboratory handling and stability plan for any custom multidose preparation.
Selank Mechanism of Action Research
Selank is a synthetic heptapeptide based on the tuftsin sequence. Human studies have examined anxiety-related clinical measures, leu-enkephalin metabolism, EEG response patterns, and functional brain connectivity after Selank exposure[1][2][4]. Intranasal drops or solution are the delivery methods reported in the primary human research summarized on this page.
The vial calculation is concentration based. Dividing 10,000 mcg by the measured final volume gives mcg per mL. Multiplying that concentration by the verified pump output gives mcg per actuation.
Synthetic Peptide Selank, Tuftsin, and GABA Research
Synthetic peptide Selank is a tuftsin analog. In that limited structural sense, Selank is a synthetic analog of a naturally occurring immune-related peptide fragment. Preclinical findings support a Selank and GABA research hypothesis, but they do not justify saying that Selank acts through GABA alone[7]. Studies suggest that Selank may influence several molecular and network-level measures; the administration of Selank, formulation, route, and experimental population still define what each result means. The administration of the peptide in one model cannot validate a different protocol.
A responsible Selank dosage guide or Selank dosing guide should keep research findings separate from calculation examples. Claims about the benefits of Selank or Selank benefits require study-specific context. Existing evidence does not establish Selank safe for unsupervised use, and phrases such as Selank for anxiety describe a research topic rather than a clinical recommendation.
Selank Peptide Findings, Safety Data, and Limits
Selank findings should be read together with the population, amount, formulation, and study design.
- The 2008 comparative study reported similar anxiety-related effects for Selank and medazepam, with additional anti-asthenic and psychostimulant observations in the Selank group[1]. A separate 2014 comparative study evaluated Selank and phenazepam in 60 participants with anxiety-spectrum or somatoform diagnoses[3].
- In the 2012 GAD study, 40% of participants were classified as rapid responders during days 1 to 3, while 60% showed a gradual response pattern through day 14[2].
- The healthy-volunteer neuroimaging study examined functional connectivity after one intranasal Selank exposure rather than a repeated clinical course[4].
- The current manufacturer instruction lists unpleasant taste sensations and possible allergic reactions among reported adverse effects[8].
- Pump output, formulation, nasal condition, and administration technique can affect the delivered amount and deposition pattern[5][6].
Selank Nasal Administration Controls
Consistent technique improves the value of recorded research observations.
- Pump specification: Record the stated or measured mL per actuation.
- Priming status: Document first use, repriming, and any missed actuations.
- Actuation technique: Keep bottle orientation, stroke length, and stroke force consistent.
- Nasal condition: Record congestion, irritation, or other conditions that could affect deposition.
- Formulation details: Record the vehicle, final volume, concentration, container, and storage conditions.
- Actuation count: Track actuations from priming through final use to identify tail-off and residual volume.
Metered Nasal Spray Technique
Use a standardized device procedure so the recorded amount remains consistent across research observations.
- Inspect the labeled concentration and confirm the actuator output before use.
- Prime or reprime the pump according to the manufacturer instructions.
- Keep the bottle in the specified orientation and use one complete, smooth stroke.
- Record each actuation immediately, including priming actuations.
- Wipe the nozzle with a clean material appropriate for the device and replace the cap.
- Return the bottle to its documented storage condition after the research procedure.
Important Note
This page summarizes published Selank research and concentration calculations for educational purposes. It is not medical advice, does not establish a validated clinical protocol, and is not a recommendation for human use.
Selank Dosage Questions and Evidence Limits
This research guide separates vial mathematics from the findings of clinical studies. The 10 mg vial changes the available peptide mass and the number of nominal actuations; it does not create a new validated dose, dosing protocol, or treatment cycle.
What does a 10 mg Selank vial change?
A 10 mg vial contains 10,000 mcg of Selank peptide. Bringing that amount to a measured 5 mL final volume produces 2 mg/mL, while a measured 10 mL final volume produces 1 mg/mL. With a verified 0.10 mL metered nasal spray bottle, those concentrations equal 200 mcg or 100 mcg per actuation. The vial strength does not determine the research dose; concentration, actuator output, formulation, and the cited study design all matter.
Where does the published Selank dosing information come from?
The human evidence includes comparative clinical research in participants with anxiety-spectrum diagnoses or neurasthenia, plus a healthy-volunteer neuroimaging experiment[1][2][3][4]. These clinical studies reported specific intranasal formulations, populations, durations, and outcome measures. They do not establish a universal Selank dosing protocol, and a calculated amount for a custom preparation is not equivalent to the preserved product used in a clinical trial.
Is intranasal Selank interchangeable with Selank injection?
No. The primary human sources summarized here used intranasal Selank. Search terms such as Selank injection, subcutaneous injection, or injectable Selank describe a different route and should not be converted from the nasal research amounts on this page. Route, absorption, container, and formulation differ. This page therefore limits its principal calculation table to intranasal concentration and actuator math.
How do Selank and Semax differ?
Selank and Semax are distinct synthetic peptide research compounds, even though both have been studied through intranasal administration and are sometimes discussed together. Selank is a tuftsin analog; Semax is derived from an adrenocorticotropic hormone fragment. A Selank vs Semax comparison cannot make their dose, mechanism of action, safety data, or research protocol interchangeable. The Semax 10 mg dosage protocol keeps its own calculations and evidence separate.
What has research examined about the mechanism of action of Selank?
Selank is a synthetic heptapeptide and tuftsin analog. Human work has examined anxiety-related measures, EEG response patterns, enkephalin metabolism, and functional connectivity after Selank administration[1][2][4]. Preclinical research has also examined the influence of Selank on expression of genes involved in GABAergic neurotransmission[7]. These findings help frame hypotheses about the anxiolytic and nootropic peptide literature, but they do not prove a clinical benefit, establish that Selank is safe, or validate a self-directed dose.
Is Selank FDA-approved?
Selank is not FDA-approved in the United States. Published Russian clinical studies and a registered product formulation provide research context, but regulatory status and formulation controls differ by jurisdiction. The page uses FDA nasal-product guidance only to explain device variables such as pump output, priming, dose uniformity, and bottle exhaustion[6]. It is not evidence that FDA has evaluated or approved Selank.
Why can the delivered amount differ from the calculation?
Reconstitution math assumes an exact final volume and a verified actuator output. Real devices can lose volume during priming, retain liquid in the container, or change output near bottle exhaustion. Nasal irritation, congestion, pump orientation, and an incomplete stroke can also affect deposition. Record the actual device specification and research conditions rather than treating the nominal actuation count as guaranteed delivery[5][6].
How should research terminology be interpreted?
Published papers describe Selank as an anxiolytic peptide, while reviews may also discuss it as a nootropic peptide. Those labels identify research categories; they do not establish therapeutic use. Semax and Selank must remain separate because their sequences, evidence bases, and proposed mechanisms differ. The effect of Selank reported in one experiment cannot be generalized to another formulation or route. Likewise, a research cycle or dosing cycle is a study-design period, not a validated clinical standard. References to an anxiolytic effect or a nootropic effect on this page summarize cited observations rather than a recommendation. For this peptide, identity, peptide concentration, and peptide formulation must be documented separately. A nasal spray calculation, nasal spray device specification, and nasal spray formulation must be reviewed together.
References
-
Zozulia et al. (2008)
Human comparative study of Selank in adults with generalized anxiety disorder or neurasthenia. The PubMed record summarizes the study design and population. -
Syunyakov et al. (2012)
Rapid and slow response during treatment of generalized anxiety disorder with peptide anxiolytic Selank. Reports 2,700 mcg per day intranasally and a 900 mcg pharmaco-EEG exposure. -
Medvedev et al. (2014)
Comparative human study of Selank and phenazepam in 60 participants with anxiety-spectrum or somatoform diagnoses. -
Panikratova et al. (2020)
Functional connectomic study of acute intranasal Selank exposure in healthy volunteers. -
Trows et al. (2014)
Analytical challenges and regulatory requirements for nasal drug products in Europe and the United States. Reviews pump output and device variables. -
U.S. Food and Drug Administration
Nasal Spray and Inhalation Solution, Suspension, and actuation Drug Products. CMC guidance covering pump delivery, priming, dose uniformity, and product performance. -
Volkova et al. (2016)
Preclinical study of Selank exposure and expression of genes involved in GABAergic neurotransmission. -
Pure Lab Peptides
Selank 10 mg research product page and batch documentation.
Related research, protocols, and guides
Explore the available research context, protocol variants or comparisons, and practical guides. When vial-size variants exist, they remain separate because vial strength, concentration, and syringe-unit calculations can differ. Related compounds and blends are comparisons only, not interchangeable.
Research overview
Other vial-size protocols
Related protocols and comparisons